Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses

Xiu-wei Guo; Nai-dong Hu; Gui-zhi Sun; Meng Li; Pei-tong Zhang

doi:10.1007/s11655-017-2951-5

Your Location：

Home >

Browse articles >

Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses

Updated：2021-08-27

- Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses
- Chinese Journal of Integrative Medicine Vol. 24, Issue 3, Pages: 227-231(2018)
- Affiliations：
  
  1. Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  2. Department of Oncology, The East Campus of Dongzhimen Hospital, Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-017-2951-5
  CLC：
- Published：2018，
  
  Published Online：18 October 2017，
Scan for full text
Guo, Xw., Hu, Nd., Sun, Gz. et al. Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses., Chin. J. Integr. Med. 24, 227–231 (2018). https://doi.org/10.1007/s11655-017-2951-5

Xiu-wei Guo, Nai-dong Hu, Gui-zhi Sun, et al. Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses. [J]. Chinese Journal of Integrative Medicine 24(3):227-231(2018)
Guo, Xw., Hu, Nd., Sun, Gz. et al. Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses., Chin. J. Integr. Med. 24, 227–231 (2018). https://doi.org/10.1007/s11655-017-2951-5 DOI：

Xiu-wei Guo, Nai-dong Hu, Gui-zhi Sun, et al. Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses. [J]. Chinese Journal of Integrative Medicine 24(3):227-231(2018) DOI： 10.1007/s11655-017-2951-5.

摘要

To assist decision-makers interpret and choose among conflfl icting meta-analyses

as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule (参一胶囊

SC) plus chemotherapy versus chemotherapy of non-small cell lung cancer (NSCLC). A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC. Meta-analyses only composed of randomized controlled trials (RCTs) met the inclusion criteria. Two authors individually estimated the quality of meta-analysis and extracted data. The Jadad decision algorithm was applied to guarantee which meta-analysis provided the best original evidence. A total of 5 meta-analyses were included. All the studies composed of RCTs or quasi-RCTs and were regarded as level-II evidence. The scores of the Assessment of Multiple Systematic Reviews ranged from 3 to 6 (median 4). A high-quality meta-analysis with more RCTs was chosen

which suggested that SC plus chemotherapy could increase incidence of short-term efficacy

improve the quality of life and survival rate in comparison to chemotherapy. However

there was no statistically significant difference between SC plus chemotherapy and chemotherapy regarding chemotherapy-induced side effect

such as liver and kidney function obstacle

leukopenia

hemoglobin decrement and gastrointestinal adverse reaction. Based on the best available evidence

treatment effect of SC plus chemotherapy was better than chemotherapy and did not increase side effects. Therefore

SC plus chemotherapy may be superior to chemotherapy for treating NSCLC. However

due to some limitations

SC plus chemotherapy should be cautiously considered

and further high-quality meta-analyses are needed.

Abstract

To assist decision-makers interpret and choose among conflfl icting meta-analyses

as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule (参一胶囊

which suggested that SC plus chemotherapy could increase incidence of short-term efficacy

improve the quality of life and survival rate in comparison to chemotherapy. However

there was no statistically significant difference between SC plus chemotherapy and chemotherapy regarding chemotherapy-induced side effect

such as liver and kidney function obstacle

leukopenia

hemoglobin decrement and gastrointestinal adverse reaction. Based on the best available evidence

treatment effect of SC plus chemotherapy was better than chemotherapy and did not increase side effects. Therefore

SC plus chemotherapy may be superior to chemotherapy for treating NSCLC. However

due to some limitations

SC plus chemotherapy should be cautiously considered

and further high-quality meta-analyses are needed.

关键词

non-small cell lung cancerShenyi CapsuleChinese Medicinechemotherapyintegrative treatmentsystematic reviewmeta-analysis

Keywords

non-small cell lung cancerShenyi CapsuleChinese Medicinechemotherapyintegrative treatmentsystematic reviewmeta-analysis

references

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.

Chen XL, Duan XM, Zhao HF, Teng YL. Treatment strategy for molecular targeted drugs on non-small cell lung cancer. China Pharm (Chin) 2014;25:2080–2082.

Zhang X, Ye BD, Chen D, Wu DJ, Zhao YH. Progress on anti-tumor effects and mechanisms of ginsenoside-Rg3. Chin Arch Tradit Chin Med (Chin) 2013;31:328–330.

Chen SJ, Li RZ. Clinical observation of Canyi Capsule combined with GP regimen in the treatment of advanced nonsmall cell lung cancer. Contemp Med (Chin) 2012;18:1–2.

Li CY, Li QY, Xu J. Clinical observation of Canyi Capsule combined with GP regimen in the treatment of advanced non-small cell lung cancer. Cancer Res Prev Treat (Chin) 2012;39:1125–1127.

Li HB, Liu WL, Zhang QY, Kang XM, Zhao WH. The efficacy analysis of low-dose cyclophosphamide combined with ginsenoside Rg3 on advanced non small cell lung cancer. Pract Oncol J (Chin) 2006;20:18–20.

Liu H, Hou W, Wang H, Lin HS. Clinical research on Shenyi Capsule combined with gefitinib for advanved non-small cell lung cancer: a report of 50 cases. J Tradit Chin Med (Chin) 2012;53:933–935, 966.

Liu SQ, Sun LX, Ban LY, Zhou T. Ginsenoside Rg3 capsules combined NP regimen in the treatment of advanced non-small cell lung cancer. Chin Clin Oncol (Chin) 2007;12:847–849.

Liu XG, Yang HB, Li L, Xing LN. Effect observation of Shenyi Capsule combined chemotherapy for treatment of advanced non-small cell lung cancer. Jilin Med J (Chin) 2009;30:2319–2320.

Liu Y, Liu S, Xu CA. Clinical observation of chemotherapy plus Shenyi Capsule for treatment of advanced non-small cell lung cancer. Shanxi Med J (Chin) 2007;36:554–556.

Qi CW, Zhang HT. Ginsenoside Rg3 combined GP regimen in the treatment of advanced non-small cell lung cancer. J Clin Med Pract (Chin) 2011;15:121–122.

Shao HL. Clinical observation on Shenyi Capsule combined with docetaxel for elderly patients with advanced non-small cell lung cancer. Shanxi Med J (Chin) 2013;42:738–740.

Shi MQ, Feng JF, Pan LX, Zhou ZF. Clinical observation of treating non-small-cell lung cancer by chemotherapy and Shenyi Capsule. Chin Clin Oncol (Chin) 2006;11:193–194, 197.

Sun Yan, Lin HS, Zhu YZ, Feng JF, Chen ZT, Li GS, et al. A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine + cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Chin) 2006;9:254–258.

Wang XQ, Zhang M. Effect observation of Shenyi Capsule combined with radiation and chemotherapy treatment for elderly advanced non-small cell lung cancer. J Pract Med (Chin) 2013;29:1885–1886.

Xu S, Zhao YX, Long D. Effect of Canyi Capsule combined with single chemotherapy drug in maintenance treatment for patients with advanced non-small cell lung cancer. J Guangzhou Univ Tradit Chin Med (Chin) 2013;3:337–340.

Qin SK, Chen YX, Wang L, Liu XF, He ZM, Wang JS. Clinial study on qi deficiency patients with non-small cell lung cancer (NSCLC) treated by Shenyi Capsule. Chin Clin Oncol (Chin) 2001;04:327–329,331.

Lin HS, Piao BK, Li SQ. Phase II clinical trial report of treating lung cancer with Shenyi Capsule. Chin J Clin Oncol (Chin) 2002;4:276–279.

Chen WM, Yao Y, Shi ZZ. Observation of curative effect of combined 20(r)-ginsenoside Rg3 with chemotherapy with non small cell lung cancer. Mil Med J South China (Chin) 2005;1:4–6.

Wang Y, Liu JL, Zhao HL, Yang MP, Li X, Liu L. Curative effect observation of ginseng saponins Rg3 capsule combined With chemotherapy for treatment of advanced non-small cell lung cancer. Pract Oncol J (Chin) 2011;25:33–35.

Du LX. clinical observation of Shenyi Capsule auxiliary treatment of advanced non-small cell lung cancer. Neimongol J Tradit Chin Med (Chin) 2014;33(34):7.

Pang M. Correlation studies of the near future curative effect of Shenyi Capsule adjuvant chemotherapy treatment on advanced non-small cell lung cancer and the serum levels changes of VEGF/bFGF [dissertation]. Jinan: Jinan University; 2012:47.

Tu H. Curative effect observation of serum vascular endothelial growth factor of ginseng saponins Rg3 plus chemotherapy for treatment of advanced non-small cell lung cancer patients [dissertation]. Fuzhou: Fujian University Traditional Chinese Medicine; 2008:30.

Zhu JP, Yu LK, Hao KK, Zhang Y, Sun ZK. Treat non-small cell lung cancer with Shenyi Capsule plus chemotherapy: a systematic review. Liaoning J Tradit Chin Med (Chin) 2009;9:1444–1447.

Hu SS, Zhou LK, BA Y, Li HL, Zhu CH. A meta-analysis of ginsenoside Rg3 for non-small cell lung cancer. Clin Oncol Cancer Res 2011;8:175–180.

Xia HX, Jiao LB, Hu W. A meta-analysis of therapeutic efficacy of Shenyi Capsule combined with chemotherapy for advanced non-small cell lung cancer. China Pharm (Chin) 2014;20:1887–1891.

Xu LN, Zhang NZ. Clinical effect and safety meta-analysis of adjuvant chemotherapy of ginseng 1 capsule for nonsmall cell lung cancer. Yunnan J Tradit Chin Med Mater Med (Chin) 2015;7:14–16.

Fang SS, Ge W, Song J, Luo W, Chen C. System evaluation of the effectiveness and safety of Rg3 combined with chemotherapy for advanced non-small cell lung cancer. China Med Herald (Chin) 2015;35:87–92.

Mascarenhas R, Cvetanovich GL, Sayegh ET, Verma NN, Cole BJ, Bush Joseph C, et al. Does double-bundle anterior cruciate ligament reconstruction improve postoperative knee stability compared with single-bundle techniques? A systematic review of overlapping meta-analyses. Arthroscopy 2015;31:1185–1196.

Zhao JG, Wang J, Wang C, Kan SL. Intramedullary nail versus plate fixation for humeral shaft fractures: a systematic review of overlapping meta-analyses. Medicine (Baltimore) 2015;94:e599.

Mascarenhas R, Chalmers PN, Sayegh ET, Bhandari M, Verma NN, Cole BJ, et al. Is double-row rotator cuff repair clinically superior to single-row rotator cuff repair: a systematic review of overlapping meta-analyses. Arthroscopy 2014;30:1156–1165.

Zhao JG, Wang J, Long L. Surgical versus conservative treatments for displaced midshaft clavicular fractures: a systematic review of overlapping meta-analyses. Medicine (Baltimore) 2015;94:e1057.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.

Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal. J Bone Joint Surg Am 2003;85:1–3.

Shea BJ, Grimshaw JM, Wells GA, Boer M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:1–7.

Jadad AR, Cook DJ, Browman GP. A guide to interpreting discordant systematic reviews. CMAJ 1997;156:1411–1416.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

A systematic review and meta-analysis of type 2 diabetes mellitus treatment based on the “three-typed syndrome differentiation” theory in Chinese medicine

Individual patient data meta-analysis is needed in Chinese medical research

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Efficacy and safety of Flos Abelmoschus manihot (Malvaceae) on type 2 diabetic nephropathy: A systematic review

Potassium Dehydroandrographolide Succinate Injection for the treatment of child epidemic parotitis: A systematic review and meta-analysis

Related Author

No data

Related Institution

Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

China Academy of Chinese Medical Sciences

School of Basic Medical Science, Shandong University of Traditional Chinese Medicine

Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰